1. Master – shall I write your article? Pushing the genie back into the bottle

   • L. Offerhaus

   EDITORIAL Pages: 779 - 780

2. Methodological and political issues in clinical pharmacology research by the year 2000

   • X. Carné
   • J. -A. Arnaiz

   SPECIAL ARTICLE Pages: 781 - 785

3. Probucol reduces lysophosphatidylcholines in low-density lipoprotein

   • M. Yoshinari
   • A. -H. Shi
   • M. Fujishima

   CLINICAL TRIALS Pages: 787 - 792

4. Haemodynamic interactions between the novel calcium sensitiser levosimendan and isosorbide-5-mononitrate in healthy subjects

   • S. Sundberg
   • L. Lehtonen

   CLINICAL TRIALS Pages: 793 - 799

5. The efficacy of buffered ketoprofen in postoperative pain after third molar surgery

   • R. A. Seymour
   • H. Watkinson
   • U. Moore

   CLINICAL TRIALS Pages: 801 - 806

6. Structure–effect relationships of amiodarone analogues on the inhibition of thyroxine deiodination

   • H. R. Ha
   • B. Stieger
   • F. Follath

   PHARMACODYNAMICS Pages: 807 - 814

7. Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease

   • I. Alafuzoff
   • S. Helisalmi
   • K. Koivisto

   PHARMACODYNAMICS Pages: 815 - 819

8. CYP2C19 polymorphism effect on phenobarbitone

   • K. Mamiya
   • A. Hadama
   • S. Higuchi

   PHARMACOKINETICS AND DISPOSITION Pages: 821 - 825

9. Simultaneous modelling of flosequinan and its metabolite

   • J. K. Lindsey
   • J. Wang
   • I. D. Hind

   PHARMACOKINETICS AND DISPOSITION Pages: 827 - 836

10. Pharmacokinetics and pharmacodynamics of the novel H₁-receptor antagonist emedastine in healthy volunteers

    • B. Jansen
    • U. Graselli
    • M. Müller

    PHARMACOKINETICS AND DISPOSITION Pages: 837 - 841

11. Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug–drug interactions

    • M. Katoh
    • M. Nakajima
    • T. Yokoi

    PHARMACOKINETICS AND DISPOSITION Pages: 843 - 852

12. Human halothane metabolism, lipid peroxidation, and cytochromes P ₄₅₀2A6 and P ₄₅₀3A4

    • E. D. Kharasch
    • D. C. Hankins
    • K. Cox

    PHARMACOKINETICS AND DISPOSITION Pages: 853 - 859

13. Circadian variation of the urinary 6β-hydroxycortisol to cortisol ratio that would reflect hepatic CYP3A activity

    • M. Ohno
    • I. Yamaguchi
    • J. Azuma

    PHARMACOKINETICS AND DISPOSITION Pages: 861 - 865

14. Pharmacokinetics of a glycine site antagonist (gavestinel) following multiple dosing in patients with acute stroke

    • J. F. Hoke
    • A. G. Dyker
    • K. R. Lees

    PHARMACOKINETICS AND DISPOSITION Pages: 867 - 872

15. The impact of problem-based pharmacotherapy training on the competence of rational prescribing of Yemen undergraduate students

    • N. A. G. M. Hassan
    • A. A. Abdulla
    • T. P. G. M. de Vries

    PHARMACOEPIDEMIOLOGY AND PRESCRIPTION Pages: 873 - 876

16. Influence of CYP2D6*2 and CYP2D6*4 alleles on phenotype in polymedicated depressed inpatients: therapeutic consequences?

    • E. Haffen
    • P. Vandel
    • P. R. Bechtel

    LETTER TO THE EDITORS Pages: 877 - 879

17. How did such a bad report get published in the EJCP?

    • A. Herxheimer

    LETTER TO THE EDITORS Pages: 881 - 881

18. Co-ordinating editor's comments on the letter to the editors by A. Herxheimer

    • Rune Dahlqvist

    COMMENTS Pages: 883 - 884